GLP-1 Drugs Are Rewriting Your Self-Funded Plan's Budget. The Math Is Brutal.

GLP-1 medications are now one of the largest single cost drivers in self-funded employer health plans. For mid-market employers, even a handful of members on these drugs can shift your annual claims picture by six figures.

The 2025 KFF Health Tracking Poll found that 1 in 8 adults is currently taking a GLP-1 drug. Nearly 1 in 5 has taken one at some point. That's not a niche category anymore. That's a population-level cost event sitting inside your plan.

What do GLP-1 drugs actually cost a self-funded plan per member?

Monthly list prices for Ozempic reach $1,028 and Wegovy $1,349 per injection, according to Forbes Health data. Under actual employer plan coverage, Blue Cross Blue Shield analysis puts the net employer cost at up to $766 per member per month after discounts and rebates. That's $9,192 per member per year, before any associated medical spend.

Put 15 members on Wegovy at those rates. You're looking at $137,880 in annual drug spend from one medication category. On a 300-person plan, that's a line item that didn't exist five years ago.

And rebates aren't the rescue they used to be. The ICER White Paper notes that semaglutide revenues grew 89% in a single year, with over 70% of that coming from the U.S. market. Rebates paid back to payers may amount to more than 50% of gross sales in some cases, but your share of that depends entirely on your PBM contract language.

How much can GLP-1 utilization move your total premium or renewal?

BCBS projects that GLP-1 medications like Ozempic and tirzepatide may increase employer health premiums by up to 14%. That's not a forecast for a single high-utilization employer. That's an industry-wide projection.

For a self-funded plan, the number isn't abstract. It shows up directly in your claims run rate and stop-loss renewal.

Medicare data puts the trajectory in context. KFF tracking shows two million Medicare Part D enrollees took Ozempic in 2024, up from fewer than 150,000 in 2019. Nearly one million took Mounjaro, up from 54,000 in 2022. Total gross Medicare spending on these drugs went from $57 million in 2018 to $5.7 billion in 2022, per ICER White Paper data. Commercial plan spending is following the same curve.

Your stop-loss carrier has already seen this data. Expect it to show up in how they price your renewal if you haven't managed this category deliberately. The article Why Your Stop-Loss Premium Jumps 30% When Claims Only Grew 10% explains exactly how high-cost drug trends get amplified at renewal time.

Does covering GLP-1s actually save money downstream?

This is the argument you'll hear from brokers and drug manufacturers: cover GLP-1s now and avoid diabetes, cardiovascular events, and hospitalizations later. The data is mixed, and the structural problem is real. Preliminary real-world data from Milliman, cited by the American Academy of Actuaries, suggests increased GLP-1 adherence may lower medical costs for certain chronic conditions. But those offsets don't yet fully recover the high cost of the drugs.

There's also a timing problem that doesn't get talked about enough. Employees change jobs. They age into Medicare. They move to a spouse's plan. You pay for three years of Wegovy and your competitor's health plan captures the cardiac savings.

Even conservative modeling of Medicare expansion, with 5% uptake, 30% additional discount, and 20% adherence, projects net GLP-1 spending reaching $17.9 billion over 10 years, per a peer-reviewed PMC/NIH study. The long-run savings thesis is real in aggregate. For a 200-person employer over a 3-year stop-loss cycle, it's nearly impossible to close.

What controls do self-funded employers actually have?

More than fully insured employers, but only if you use them. Self-funded plans can design formulary tiers, require prior authorization with documented clinical criteria, set quantity limits, and exclude obesity-indication coverage while retaining diabetes coverage. These aren't the same decision. Ozempic for Type 2 diabetes and Wegovy for weight loss are different products with different cost profiles and different clinical justifications.

You can also carve out GLP-1 management to a specialty pharmacy or a PBM with pass-through contract terms. The article Buying GLP-1s Without the PBM: What Direct Sourcing Actually Looks Like in 2026 walks through what that structure looks like in practice. Haven't reviewed your PBM rebate pass-through contract language for this category specifically? That's the first place to start.

Stop-loss exposure is the other critical variable. Some carriers are beginning to carve GLP-1s out of specific deductible calculations or applying surcharges at renewal for plans with high utilization. Review How to Read a Stop-Loss Quote Without Getting Buried by the Fine Print before your next renewal conversation.

What should you decide before your 2027 plan year?

The decision isn't binary. It's not "cover GLP-1s" or "don't cover GLP-1s." The real decision is whether you have a written, deliberate policy with clinical guardrails, cost controls, and stop-loss alignment, or whether you're absorbing utilization without a strategy.

Bank of America reportedly spends over $250 million on GLP-1 drugs. They have a treasury department and actuaries running that math. You have a benefits renewal meeting. The asymmetry matters.

Pull your current GLP-1 claims now. Know the member count, the drugs, and the indications. Then have the formulary, prior auth, and stop-loss conversation with specific numbers in front of you.

Frequently asked questions

Should a self-funded employer cover GLP-1 drugs for weight loss?

There's no universal answer. Covering GLP-1s for obesity can improve employee health outcomes, but real-world data from Milliman shows the downstream medical cost offsets don't yet fully recover drug costs. The better question is whether you have active clinical criteria, prior authorization requirements, and quantity limits in place. Covering without controls is the expensive mistake. Use the Benefits Control System to map your current formulary against your claims exposure before making this call.

How does GLP-1 spending affect stop-loss renewals?

High GLP-1 utilization directly increases your claims run rate, which drives stop-loss carriers to either raise premiums, tighten attachment points, or both. Some carriers are now applying surcharges or exclusions specific to GLP-1 categories. Don't assume your current specific deductible accounts for this drug trend. Your out-of-pocket exposure at renewal is likely higher than your broker has modeled.

What's the difference in cost between covering Ozempic for diabetes versus Wegovy for weight loss?

Ozempic (semaglutide for Type 2 diabetes) and Wegovy (semaglutide for obesity) are the same molecule at different doses, but carry different list prices and different rebate profiles. Monthly list prices reach $1,028 for Ozempic and $1,349 for Wegovy. Most employers choose to cover the diabetes indication with prior auth and exclude or restrict the obesity indication. That line matters in your plan document and your formulary design.

Can a self-funded employer exclude GLP-1s from coverage entirely?

Yes, self-funded ERISA plans have broad latitude to design their own formularies, including excluding specific drug categories. However, excluding GLP-1s for diabetes treatment while covering other diabetes medications may create inconsistency worth reviewing with your legal counsel. Excluding obesity-indication coverage is more straightforward. State mandates that might require coverage generally don't apply to self-funded plans under ERISA preemption.

Where can I see how GLP-1 spending compares to other specialty drug categories hitting self-funded plans?

The specialty drug pipeline is producing multiple high-cost categories simultaneously. The article Specialty Drug Pipeline 2027: The Claims Hitting Your Plan Next Year covers what's coming beyond GLP-1s, including cell and gene therapies and other biologics that are beginning to appear in mid-market claims data.